October 9 from 5:30 pm – 8:00 pm HST
Supported by United Therapeutics, A Public Benefit Corporation
Program Description
Join us for an informative case-based discussion about pulmonary hypertension associated with interstitial lung disease (PH-ILD). Expert faculty will explore the latest disease state information, clinical trial data, how to identify patients with PH-ILD and, where appropriate, start them on treatment.
Register Now! www.phildsymposium.com
Questions? Please contact Brandy Triplett at United Therapeutics ([email protected])
This presentation is intended for practicing US healthcare providers only. This invitation is nontransferable. Food and beverage costs and any other transfers of value provided to applicable healthcare prescribers will be reported under any/all state and federal laws.
This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2023 conference sessions. This event is not endorsed by CHEST and does not reflect the views or opinions of CHEST.
Speakers
Jean Elwing, MD, FCCP
Professor of Medicine
Director, Pulmonary Hypertension Program
University of Cincinnati Health
Cincinnati, OH
Mary Beth Scholand, MD, FCCP
Professor of Medicine
Director, Interstitial Lung Disease Clinic
University of Utah Health
Salt Lake City, UT
Namita Sood, MD, FCCP
Professor of Medicine, Division of Pulmonary
Critical Care & Sleep Medicine
Director, UC Davis Advanced Lung Disease Program
Director, UC Davis Interstitial Lung Disease Program
Director, Pulmonary Hypertension Clinical Trials
University of California–Davis
Sacramento, CA